Figure 1.
CONSORT statement and workflow of the PREDICT study.
EC-T, epirubicin/cyclophosphamid followed by docetaxel; Pts, patients; pCR, pathologic complete response.
Table 1.
Baseline characteristics of the PREDICT cohort.
Table 2.
Evaluation of pathological complete response (pCR) to neoadjuvant chemotherapy.
Table 3.
Association of LPBC status with clinical parameters.
Table 4.
Univariate and multivariate analysis.